Correspondence to editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e219. CrossRef
Maternal liver function and adverse pregnancy outcomes in Chinese women with HIV: a cohort study E Wu, Jun-Tao Ni, Lijun Xu, Yin-wei Chen, Xiao-Hui Zhang BMC Public Health.2026;[Epub] CrossRef
Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China Ruya Zhu, Caicai Xu, Suwen Jiang, Jianping Xia, Boming Wu, Sijia Zhang, Jing Zhou, Hongliang Liu, Hongshan Li, Jianjun Lou European Journal of Medical Research.2025;[Epub] CrossRef
GDM-BC: Non-invasive body composition dataset for intelligent prediction of Gestational Diabetes Mellitus Chen Zheng, Tong Qing, Mao Li, Shujuan Liao, Biru Luo, Chenwei Tang, Jiancheng Lv Computers in Biology and Medicine.2025; 192: 110176. CrossRef
Влияние неалкогольной жировой болезни печени на течение беременности и неонатальные исходы: обзор литературы
Виталий Анатольевич Резник, Юрий Павлович Успенский, Полина Юрьевна Бухмирова, Александр Александрович Гнутов, Виталий Антонович Добренко University therapeutic journal.2025; 7(3): 7. CrossRef
Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim JHEP Reports.2024; 6(4): 101033. CrossRef
Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study Seung Mi Lee, Geum Joon Cho, Won Young Wi, Errol R. Norwitz, Bo Kyung Koo, Jeesun Lee, Young Mi Jung, Soo Heon Kwak, Chan-Wook Park, Jong Kwan Jun, Sae Kyung Joo, Min-Jeong Oh, Won Kim, Joong Shin Park Hepatology International.2023; 17(2): 367. CrossRef
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies George Agyapong, Farzaneh Dashti, Bubu A. Banini Annals of the New York Academy of Sciences.2023; 1526(1): 16. CrossRef
Case Report:Pregnancy and birth in a mild phenotype of Alström syndrome Luca Marozio, Francesca Dassie, Gianluca Bertschy, Emilie M. Canuto, Gabriella Milan, Stefano Cosma, Pietro Maffei, Chiara Benedetto Frontiers in Genetics.2022;[Epub] CrossRef
Background/Aims Maternal and fetal outcomes in pregnant patients with Non-alcoholic fatty liver disease (NAFLD) have been largely unexplored. To determine the level of evidence associated with maternal and fetal outcomes in pregnant women with NAFLD.
Methods We conducted a comprehensive literature search. The studies included pregnant patients with a previous, current or subsequent diagnosis of NAFLD. We used a random-effects model using odds ratios (OR) with 95% confidence intervals (CI).
Results Twenty-two studies, with 13,641 female NAFLD patients were reviewed. The results highlight that NAFLD patients had a statistically significant increased likelihood of baseline diabetes mellitus (OR, 6.00; 95% CI, 2.21–16.31; P<0.001; n=7), baseline Hypertension (OR, 3.75; 95% CI, 2.13–6.59; P<0.001; n=4), gestational hypertension (OR, 1.83; 95% CI, 1.03–3.26; P=0.041; n=2), and pre-eclampsia (OR, 2.43; 95% CI, 1.46–4.04; P=0.001; n=3). The odds for a past and current history of gestational diabetes mellitus were OR, 3.78; 95% CI, 2.21–6.44; P<0.001; n=5 and OR, 3.23; 95% CI, 1.97– 5.31; P<0.001; n=6, respectively. As for fetal outcomes, pregnant NAFLD patients were significantly more likely to have a premature birth (OR, 2.02; 95% CI, 1.44–2.85; P<0.001; n=4), large for gestational age birth (OR, 2.01; 95% CI, 1.72–2.37; P<0.001; n=2) or a history of prior miscarriage or abortion (OR, 1.15; 95% CI, 1.02–1.30; P=0.02; n=2). Egger’s regression revealed no evidence of publication bias (P>0.05).
Conclusions This meta-analysis provides pooled evidence that NAFLD is associated with a substantial increase in maternal diabetic and hypertensive complications and multiple adverse fetal outcomes. This data is important for clinicians managing these patients before, during and after pregnancy.
Citations
Citations to this article as recorded by
What role does metabolic disfunction-associated fatty liver disease play in the metabolic landscape of pregnancy? Annunziata Lapolla, Maria Grazia Dalfrà Expert Review of Endocrinology & Metabolism.2026; 21(1): 1. CrossRef
Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study Young Mi Jung, Taesu Kim, Min-Jeong Oh, Dong Hyeon Lee, Geum Joon Cho, Won Kim Hepatology International.2026; 20(1): 69. CrossRef
Non-alcoholic Fatty Liver Disease in Pregnancy: Clinical Implications, Adverse Outcomes, and Therapeutic Considerations Diego F. Wyszynski Journal of Clinical and Experimental Hepatology.2026; 16(2): 103431. CrossRef
Evaluating metabolic dysfunction-associated steatotic liver disease, associated adverse pregnancy outcomes, and postpartum maternal course utilising transient elastography with controlled attenuation parameter in pregnancy: a prospective cohort study Marcia Lange, Jeanette Rios, Cecilia Katzenstein, Theresa Worthington, Carin Carroll, Nina Rodriguez, Rachel Meislin, Pamela Argiriadi, Sonam Rosberger, Emma Rosenbluth, Rhoda Sperling, Keith Sigel, Norah A Terrault, Tatyana Kushner The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(1): e33. CrossRef
Evaluating the 2023 European Association for the Study of the Liver Guidelines for Intrahepatic Cholestasis of Pregnancy: Risk Stratification and Outcomes in Over 4,000 US Patients Nina Rodriguez, Cecilia Katzenstein, Lauren Alpert, Keith Sigel, Rhoda S. Sperling, Catherine Williamson, Tatyana Kushner American Journal of Gastroenterology.2026; 121(8): 1986. CrossRef
Higher Risk of Serious Infection in Offspring of Mothers With Biopsy‐Proven MASLD: A Nationwide Cohort Study Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson United European Gastroenterology Journal.2026;[Epub] CrossRef
Neither Metabolic Dysfunction Associated Steatotic Liver Disease Presence Nor Fibrosis Severity, By FIB4, Predicts Adverse Pregnancy Outcomes Christine Lopez, Zoe Finer, Suzanne Sharpton, Rolanda Lister, Jennifer Thompson, Christopher Lindsell, Yue Gao, Hillary Duckham, Manhal Izzy Journal of Clinical Gastroenterology.2026;[Epub] CrossRef
Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD Tianxiao Hu, Jiayu Qi, Yinuo Xu, Jia He, Qingying Tan, Jie Hao, Jing Wang, Jiewei Hong, Jianwei Wang, Lin Chen, Xiaobing Dou International Immunopharmacology.2026; 172: 116245. CrossRef
Biological determinants and outcomes of sex discrepancies in MASLD Amedeo Lonardo, Mohamad Jamalinia, Ralf Weiskirchen Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Live‐Streamed Exercise Intervention in Pregnant Women With MASLD (Live‐MASLD): Protocol for a Randomized Controlled Trial Mingyue Wang, Yuying Wu, Huimin Guan, Xiao Gao, Pingping Zhang, Youxin Wang, Enkar Nur, Antje Hebestreit, Hai‐Jun Wang, Lingling Sun, Hui Wang Annals of the New York Academy of Sciences.2026;[Epub] CrossRef
Correspondence on: metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes Hu Fu Hepatology International.2026;[Epub] CrossRef
Sex Differences in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Epidemiology, Pathophysiology, and Clinical Implications Kanica Kaushal, Smriti Singh, Ankita Anand, Gayatri Ramakrishna, Pratibha Kale, Rishabh Sharma, B.B. Rewari, Shiv K. Sarin Journal of Clinical and Experimental Hepatology.2026; 16(4): 103533. CrossRef
Quercetin Attenuates Non-Alcoholic Fatty Liver Disease in Association with the Inhibition of Hepatic IL-1β/iNOS and IL-1β/CD45 Axes of Inflammation and Fibrosis Accompanied by Reduced Endogenous Metabolites and Apoptosis Saif A. Alqahtani, Hanan H. Alshehri, Hend Ashour, Hend Abdallah, Laila Rashed, Rehab M. Badi, Muataz E. D. Mohammed, Bahjat Al-Ani, Norah M. Alzamil, Alia Albawardi, Basma E. Aboulhoda Metabolites.2026; 16(4): 284. CrossRef
Steatotic Liver Disease, Clinical Subtypes, and Adverse Perinatal Outcomes: The Prospective Fatty Liver in Pregnancy Study Tatyana Kushner, Rachel Meislin, Cecilia Katzenstein, Marcia Lange, Nina Rodriguez, Sonam Rosberger, Jeannette Rios, Lauren Alpert, Pamela Argiriadi, Tess Worthington, Carin Carroll, Joanne Stone, Emma Rosenbluth, Shaelyn Ohara, Himel Mallick, Phyllis Aug Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Maternal liver function and adverse pregnancy outcomes in Chinese women with HIV: a cohort study E Wu, Jun-Tao Ni, Lijun Xu, Yin-wei Chen, Xiao-Hui Zhang BMC Public Health.2026;[Epub] CrossRef
A First-Trimester Serum Proteomic Signature for Early Prediction of Preeclampsia: Integrated Untargeted and Targeted Mass Spectrometry with Machine Learning Natalia Starodubtseva, Alina Poluektova, Alisa Tokareva, Alexey Kononikhin, Alexander Brzhozovskiy, Anna Bugrova, Evgenii Kukaev, Zulfiya Khodzhaeva, Evgeny Nikolaev, Gennady Sukhikh Life.2026; 16(8): 1264. CrossRef
Metabolic dysfunction-associated steatotic liver disease in women across the life course Chinelo C Okigbo, Edward Springel, Hanna Blaney, Arun J Sanyal The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(8): e729. CrossRef
АССОЦИИРОВАННАЯ С МЕТАБОЛИЧЕСКОЙ ДИСФУНКЦИЕЙ СТЕАТОТИЧЕСКАЯ БОЛЕЗНЬ ПЕЧЕНИ (МАСБП) И БЕРЕМЕННОСТЬ: ОБЗОР ЛИТЕРАТУРЫ
И.Р. Гайсин, А.С. Галеев, З.Р. Губайдуллина Health, demography, ecology of finno-ugric peoples.2026; (2): 84. CrossRef
Association between the atherogenic index of plasma and non-alcoholic fatty liver disease in Korean pregnant women: secondary analysis of a prospective cohort study Rong Shuai, Yuxing He, Dongqian Yang, Yingying Zhang, Li Zhang Frontiers in Nutrition.2025;[Epub] CrossRef
GDM-BC: Non-invasive body composition dataset for intelligent prediction of Gestational Diabetes Mellitus Chen Zheng, Tong Qing, Mao Li, Shujuan Liao, Biru Luo, Chenwei Tang, Jiancheng Lv Computers in Biology and Medicine.2025; 192: 110176. CrossRef
Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson eClinicalMedicine.2025; 83: 103238. CrossRef
Global burden of metabolic disorders among women of child-bearing age, 1990–2021: a population-based study Junyu Chen, Dihan Fu, Tianqi Ma, Minghong Chen, Xuerui Wang, Jun Yi BMC Women's Health.2025;[Epub] CrossRef
Metabolic dysfunction–associated steatotic liver disease and pregnancy Monika Sarkar, Tatyana Kushner Journal of Clinical Investigation.2025;[Epub] CrossRef
The Maternal and Fetal Consequences of Metabolic Dysfunction-Associated Fatty Liver Disease and Gestational Diabetes Mellitus Thora Y. Chai, Jacob George, Dharmintra Pasupathy, Ngai Wah Cheung, Victoria L. Rudland Nutrients.2025; 17(10): 1730. CrossRef
Associations of hepatic steatosis index in early pregnancy with perinatal outcomes: A prospective birth cohort study Shaofei Su, Enjie Zhang, Shen Gao, Yue Zhang, Jianhui Liu, Shuanghua Xie, Jinghan Yu, Qiutong Zhao, Wentao Yue, Ruixia Liu, Chenghong Yin Clinical Medicine.2025; 25(4): 100343. CrossRef
Mortality and Cancer in Offspring of Mothers With Biopsy‐Proven MASLD During Pregnancy: A Nationwide Cohort Study Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson Liver International.2025;[Epub] CrossRef
Global, regional, and national time trends in prevalence of metabolic dysfunction associated steatotic liver disease among women of reproductive age: an age-period-cohort analysis for the global Burden of Disease 2021 study Jiehua Wei, Shanyu Lin, Senmao Zhang, Luying Fan, Lisa Jiang, Fan Xia, Ziye Li, Lizhang Chen, Zhiyong Zou, Tingting Wang Annals of Medicine.2025;[Epub] CrossRef
Biomarker discovery in NAFLD: insights from metabolomics and vote counting meta-analysis Pallavi Mudgal, Sonu Kumar Gupta, Sunny Malik, Rinkal B. Nith, Sunil Kumar, Rahul K, Kartikey Chaturvedi, Yashwant Kumar Metabolomics.2025;[Epub] CrossRef
Liver diseases in pregnancy: Clinical spectrum and outcomes – A review Sunita Khanam, Manisha Gupta, Alpana Agrawal, Ashok Kumar Kumar Santosh University Journal of Health Sciences.2025; 11(1): 156. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Pregnancy Hannah W. Han, Peter S. Marcus, Tse-Ling Fong Obstetrical & Gynecological Survey.2025; 80(10): 647. CrossRef
Влияние неалкогольной жировой болезни печени на течение беременности и неонатальные исходы: обзор литературы
Виталий Анатольевич Резник, Юрий Павлович Успенский, Полина Юрьевна Бухмирова, Александр Александрович Гнутов, Виталий Антонович Добренко University therapeutic journal.2025; 7(3): 7. CrossRef
Relationship between MASLD and women’s health: A review Pavlina Jancova, Khaled Ismail, Lucie Vistejnova Women's Health.2025;[Epub] CrossRef
Maternal metabolic dysfunction-associated steatotic liver disease during pregnancy and its impact on offspring steatosis Corie M. Klepper, Andrew T. Trout, Shun Dong, Lin Fei, Traci E. Stankiewicz, Jennifer Wayland, Maria E. Moreno-Fernandez, Senad Divanovic, Stavra A. Xanthakos, Emily DeFranco, Jessica G. Woo, Marialena Mouzaki Clinical Nutrition ESPEN.2025; 70: 327. CrossRef
Non-genetic risk factors of miscarriage: a comprehensive umbrella review of systematic review and meta-analysis Maedeh Arshadi, Mohammad Hasan Lotfi, Farzan Madadizadeh, Atiyeh javaheri, Moslem Taheri Soodejani Reproductive Health.2025;[Epub] CrossRef
Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions Mohamad Jamalinia, Samira Saeian, Nima Nikkhoo, Amirhossein Nazerian, Kamran Bagheri Lankarani Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Hepatocyte ballooning and steatosis in early and late gestation without liver malfunction: Effects of low protein/high carbohydrate diet Mónica Navarro-Meza, Mauricio Díaz-Muñoz, José Alfonso Cruz-Ramos, Jonathan Rafael Trinidad Gallardo, María Conchita Rodríguez Oseguera, Paola C. Bello-Medina, Ericka Alejandra De Los Ríos-Arellano, Rajesh Yetirajam PLOS ONE.2024; 19(1): e0294062. CrossRef
Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim JHEP Reports.2024; 6(4): 101033. CrossRef
Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study Ben-Gang Zhou, Jian-Lei Xia, Xin Jiang, Yan-Bing Ding, Qiang She BMC Endocrine Disorders.2024;[Epub] CrossRef
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros Pharmacological Reviews.2024; 76(3): 454. CrossRef
Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review Bianca M. Leca, Lukasz Lagojda, Chris Kite, Emmanouil Karteris, Eva Kassi, Harpal S. Randeva, Ioannis Kyrou Expert Review of Endocrinology & Metabolism.2024; 19(4): 335. CrossRef
Non-alcoholic fatty liver disease and pregnancy T. P. Shevlyukovа, I. A. Bulatovа Perm Medical Journal.2024; 41(3): 77. CrossRef
Novel insights into causal effects of maternal nonalcoholic fatty liver disease on adverse pregnancy outcomes: evidence from Human Genetics and Mendelian Randomization Study Qiuyan Luo, Guoting Liu, Qiulan Li, Jinghong Lu, Wenjing Zheng, Yukui Huang, Cun Li European Journal of Clinical Nutrition.2024; 78(12): 1041. CrossRef
Study on the mechanism of Shenling Baizhu powder on the pathogenesis of pregnancy complicated with non-alcoholic fatty liver, based on PI3K/AKT/mTOR signal pathway Yao Le, Zhijun Wang, Qian Zhang, Ling Miao, Xiaohong Wang, Guorong Han European Journal of Histochemistry.2024;[Epub] CrossRef
Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives Yang Zhang, Yifan Bu, Rui Zhao, Cheng Han Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
Experimental model of non-alcoholic fatty liver disease in pregnant rats to evaluate the effectiveness of therapy Elena V. Mozgovaia, Marina A. Kryshnia, Alexandra А. Blazhenko, Alina А. Nuzhnova, Gulrukhsor Tolibova, Tatyana G. Tral, Janna N. Toumasova, Andrey V. Korenevsky, Irina V. Zalozniaia, Victoria S. Ganzhina, Olesya N. Bespalova Journal of obstetrics and women's diseases.2024; 73(6): 116. CrossRef
Evaluation of Liver Disease in Pregnancy Gres Karim, Dewan Giri, Tatyana Kushner, Nancy Reau Clinics in Liver Disease.2023; 27(1): 133. CrossRef
Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study Seung Mi Lee, Geum Joon Cho, Won Young Wi, Errol R. Norwitz, Bo Kyung Koo, Jeesun Lee, Young Mi Jung, Soo Heon Kwak, Chan-Wook Park, Jong Kwan Jun, Sae Kyung Joo, Min-Jeong Oh, Won Kim, Joong Shin Park Hepatology International.2023; 17(2): 367. CrossRef
Elevated Hepatic Steatosis Index is Associated with the Development of Adverse Maternal, but Not Adverse Neonatal, Outcomes: A Retrospective Cohort Study Thora Y Chai, Karen Byth, Jacob George, Dharmintra Pasupathy, N Wah Cheung International Journal of Women's Health.2023; Volume 15: 589. CrossRef
Dietary intake of pregnant women with non-alcoholic fatty liver disease: A case-control study Lucas A. Chagas, Maria R. Torloni, Victor H.S. Sanchez, Bianca A. Pititto, Patrícia M. Dualib, Rosiane Mattar Clinical Nutrition ESPEN.2023; 57: 630. CrossRef
Impact of neighbourhood-level social determinants of health on healthcare utilisation and perinatal outcomes in pregnant women with NAFLD cirrhosis: a population-based study in Ontario, Canada Mary B Holdsworth, Maya Djerboua, Jennifer A Flemming Journal of Epidemiology and Community Health.2023; 77(12): 809. CrossRef
Non-alcoholic steatohepatitis in pregnancy: a case report Jonathan Cordivani, Lamy Clotilde, Boulvain Michel, Riera Catherine Bulletin of the National Research Centre.2023;[Epub] CrossRef
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time? Seung Mi Lee, Won Kim Clinical and Molecular Hepatology.2022; 28(1): 47. CrossRef
Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment Ja-Young Kwon Clinical and Molecular Hepatology.2022; 28(1): 50. CrossRef
Agreement of VNC and Spectral Photon-Counting CT in the Assessment of Normal to Minimal Hepatic Fat in Comparison with MRI David Klemm, Maximilian F. Russe, Marco Reisert, Sebastian Faby, Lukas Rohloff, Tobias Böttler, Michael Schultheiß, Fabian Bamberg, Jakob Weiß, Stephan Rau Academic Radiology.2026; 33(5): 1957. CrossRef
Artificial intelligence-assisted rapid on-site evaluation in liver biopsy: a diagnostic accuracy study Cheng-Cheng Du, Yu-Xian Chen, Chun-Hai Li, Hong- Meng, Fan-Lei Kong Frontiers in Oncology.2026;[Epub] CrossRef
Evaluating performance of non-invasive tests for fibrosis detection in MASLD with Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment Yusuf Kagzi, Abuzar Asif, Yanzhi Wang, Jacqueline Fischer, Sonu Dhillon Clinics and Research in Hepatology and Gastroenterology.2026; 50(7): 102879. CrossRef
Waist circumference partially mediates the non-linear association between TyHGB and MASLD in non-diabetic Japanese adults Yanyan Xuan, Jingbo Yu, Qi Yao Frontiers in Nutrition.2026;[Epub] CrossRef
Hepatic fibro-inflammation measured by magnetic resonance imaging iron-corrected T1 predicts extrahepatic cancer risk: a UK Biobank study Hye Yeon Chon, Seok-Jae Heo, SungA Bae, Tae Seop Lim, Ja Kyung Kim Clinical and Molecular Hepatology.2026; 32(3): 1349. CrossRef
Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role Mohammadjavad Sotoudeheian Current Protein & Peptide Science.2025; 26(1): 6. CrossRef
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Comparison of MRI and CT based deep learning radiomics analyses and their combination for diagnosing intrahepatic cholangiocarcinoma Ming Cheng, Hanyue Zhang, Yimin Guo, Peijie Lyu, Jing Yan, Yin Liu, Pan Liang, Zhigang Ren, Jianbo Gao Scientific Reports.2025;[Epub] CrossRef
Assisting the Diagnosis of Cirrhosis in Chronic Hepatitis C Patients Based on Machine Learning Algorithms: A Novel Non‐Invasive Approach Emre Dirican, Tayibe Bal, Yusuf Onlen, Figen Sarigul, Ulku User, Nagehan Didem Sari, Behice Kurtaran, Ebubekir Senates, Alper Gunduz, Esra Zerdali, Hasan Karsen, Ayse Batirel, Ridvan Karaali, Hatice Rahmet Guner, Tansu Yamazhan, Sukran Kose, Nurettin Erbe Journal of Clinical Laboratory Analysis.2025;[Epub] CrossRef
Association of CALLY index with NAFLD in U.S. adults from NHANES 2017–2020 assessed by vibration-controlled transient elastography Xunge Lin, Xiaozhen Huang, Ziqun Yi, Minran Li, Xujing Liang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
The Application of Aptamer and Research Progress in Liver Disease Cheng Xu, Yong Tan, Li-Ye Zhang, Xiao-Jie Luo, Jiang-Feng Wu, Lan Ma, Fei Deng Molecular Biotechnology.2024; 66(5): 1000. CrossRef
Case report: Chronic hepatitis C with anti-HCV positive and serum HCV RNA negative Huihui Lu, Wen Deng, Yao Lu, Lu Zhang, Yao Xie, Minghui Li Gastroenterology & Endoscopy.2023; 1(2): 120. CrossRef
Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun Journal of Clinical Medicine.2023; 12(2): 712. CrossRef
Circulating miR-122-5p, miR-92a-3p, and miR-18a-5p as Potential Biomarkers in Human Liver Transplantation Follow-Up Cristina Morsiani, Salvatore Collura, Federica Sevini, Erika Ciurca, Valentina Rosa Bertuzzo, Claudio Franceschi, Gian Luca Grazi, Matteo Cescon, Miriam Capri International Journal of Molecular Sciences.2023; 24(4): 3457. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Decreased Bleeding-Related Adverse Events Using Track Embolization with Gelatin Sponge Slurry after Percutaneous Liver Biopsy: A Propensity Score–Matched Study Sungho Koh, Hoon Kwon, Lee Hwangbo, Chang Won Kim, Suk Kim, Seung Baek Hong Journal of Vascular and Interventional Radiology.2023; 34(12): 2128. CrossRef
Correlation of Inflammatory Bowel Diseases with Liver Involvement Severity in Autoimmune Hepatobiliary Pathology: Cross-Sectional Study Olga V. Usoltseva, Andrey N. Surkov, Goar B. Movsisyan, Alexander S. Potapov, Elena A. Kulebina, Кirill A. Kulikov, Vladislav V. Chernikov Current Pediatrics.2022; 21(2): 105. CrossRef
Towards Autonomous Robotic Biopsy—Design, Modeling and Control of a Robot for Needle Insertion of a Commercial Full Core Biopsy Instrument Seyed MohammadReza Sajadi, Seyed Mojtaba Karbasi, Henrik Brun, Jim Tørresen, Ole Jacob Elle, Kim Mathiassen Frontiers in Robotics and AI.2022;[Epub] CrossRef
Risk assessment of hepatocellular carcinoma and liver‐related events using ultrasonography and transient elastography in patients with chronic hepatitis B Sung Hwan Yoo, Tae Seop Lim, Hyun Woong Lee, Ja Kyung Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jung Il Lee, Kwan Sik Lee, Seung Up Kim Journal of Viral Hepatitis.2021; 28(10): 1362. CrossRef
Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older Jong Man Kim, Jinsoo Rhu, Sang Yun Ha, Gyu-Seong Choi, Choon Hyuck David Kwon, Gaabsoo Kim, Jae-Won Joh Annals of Surgical Treatment and Research.2021; 101(5): 257. CrossRef
Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Gi Soo Youn, Tae Suk Kim, Baek Gyu Jun, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi, Ki Tae Suk Cancers.2020; 12(11): 3347. CrossRef
Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT.
Citations
Citations to this article as recorded by
Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility Chengtao Lou, Tianchen Lan, Shengjun Xu, Xinhao Hu, Jiarui Li, Ze Xiang, Shengda Lin, Xiaohui Fan, Jian Chen, Xiao Xu Gut.2026; 75(3): 646. CrossRef
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung Journal of Korean Medical Science.2026;[Epub] CrossRef
ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden Woo-Hyoung Kang, Shin Hwang, Deok-Bog Moon, Ki-Hun Kim, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Byeong-Gon Na, Sang-Hoon Kim, Sung-Min Kim, Sung-Gyu Lee Transplant International.2026;[Epub] CrossRef
Five decades of clinical ABO-incompatible liver transplantation research: a bibliometric analysis Maiwulanjiang Maimaiti, Alimujiang Mamuti, Yilizhati Azhati, Aliya Tulading, Yun-Fei Zhang, Jing Wu, Abudusalamu Tuersunmaimaiti, Chun-Hui Lv, Gang Yao, Amina Aierken, Tao Li, Tuerganaili Aji, Ying-Mei Shao, Hao Wen, Tuerhongjiang Tuxun International Journal of Surgery.2025; 111(1): 1508. CrossRef
Tailored strategies for emergency ABO-incompatible living donor liver transplantation: a series of three cases Nalini Kanta Ghosh, Kausar Makki, Yogesh Yadav, Tathagata Karan, Piyush Srivastava, Anil Agarwal, Vivek Vij Clinical Transplantation and Research.2025; 39(2): 161. CrossRef
Immunology demystified: A guide for transplant hepatologists Iva Kosuta, Tomislav Kelava, Ana Ostojic, Vibor Sesa, Anna Mrzljak, Hrvoje Lalic World Journal of Transplantation.2024;[Epub] CrossRef
Impact of Preformed Donor-specific Antibodies in Comparison to ABO Incompatibility in Living Donor Liver Transplantation: A Propensity Score–Matched Analysis Jiyoung Kim, Suk Kyun Hong, Jae-Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Minseob Kim, Youngjin Kim, Su young Hong, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh Transplantation.2024; 108(9): e229. CrossRef
Human umbilical cord mesenchymal stem cells alleviate fatty liver ischemia‐reperfusion injury by activating autophagy through upregulation of IFNγ Chenhao Xu, Xixi Fang, Bei Lu, Yisu Song, Wenzhi Shu, Zhengyang Lu, Renyi Su, Ze Xiang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2024;[Epub] CrossRef
Bile duct diffusion-weighted image hyperintensity predicts intrahepatic biliary complications after ABO-incompatible liver transplantation Kyowon Gu, Woo Kyoung Jeong, Dong Ik Cha, Jeong Ah Hwang, Jinsoo Rhu, Jong Man Kim, Gyu-Seong Choi, Sun-Young Baek European Radiology.2024; 35(1): 393. CrossRef
Impact of Baseline Anti-ABO Antibody Titer on Biliary Complications in ABO-Incompatible Living-Donor Liver Transplantation Se-Hyeon Yu, Hye-Sung Jo, Young-Dong Yu, Pyoung-Jae Park, Hyung-Joon Han, Sang-Jin Kim, Syahrul Hadi Kamarulzaman, Dong-Sik Kim Journal of Clinical Medicine.2024; 13(16): 4789. CrossRef
Consecutive disruption of intrahepatic bile ducts after ABO-incompatible living-donor re-liver transplantation: A case report Akihiko Soyama, Baglan Askeyev, Takanobu Hara, Hajime Matsushima, Tomohiko Adachi, Susumu Eguchi International Journal of Surgery Case Reports.2024;[Epub] CrossRef
Outcomes of emergency pediatric ABO-incompatible living donor liver transplantation in Korea Sunghyo An, Jongman Kim, Sang Jin Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2024; 4(2): 63. CrossRef
The fate of donor‐type ABO blood group antigen expression in liver grafts in ABO‐incompatible adult living donor liver transplantation Moon Young Oh, Haeryoung Kim, Nam‐Joon Yi, Suyoung Hong, Jeong‐Moo Lee, Sola Lee, Suk Kyun Hong, YoungRok Choi, Kwang‐Woong Lee, Kyung‐Suk Suh Journal of Hepato-Biliary-Pancreatic Sciences.2023; 30(7): 871. CrossRef
Strategies for ABO Incompatible Liver Transplantation Shekhar S. Jadaun, Shaleen Agarwal, Subhash Gupta, Sanjiv Saigal Journal of Clinical and Experimental Hepatology.2023; 13(4): 698. CrossRef
Single-dose eculizumab as part of a modified desensitization protocol for ABO-incompatible living donor liver transplantation Mario Spaggiari, Egor Petrochenkov, Giulia Bencini, Sujata Gaitonde, Jamie Benken, Grace Guzman, Jamie Berkes, Ivo Tzvetanov, Enrico Benedetti Liver Transplantation.2023; 29(8): 906. CrossRef
Pretransplant mycophenolate mofetil may be associated with reduced intrahepatic cholangiopathy in ABO-incompatible liver transplantation Jinsoo Rhu, Jong Man Kim, Gyu-seong Choi, Jae-Won Joh Liver Transplantation.2023; 29(8): 849. CrossRef
Advances and innovations in living donor liver transplant techniques, matching and surgical training: Meeting report from the living donor liver transplant consensus conference Mark Sturdevant, Swaytha Ganesh, Benjamin Samstein, Elizabeth C. Verna, Manuel Rodriguez‐Davalos, Vineeta Kumar, Marwan Abouljoud, Oya Andacoglu, Medhat Askar, Dieter Broering, Juliet Emamaullee, Jean C. Emond, Christine E. Haugen, Michelle T. Jesse, Mure Clinical Transplantation.2023;[Epub] CrossRef
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You World Journal of Gastrointestinal Surgery.2023; 15(12): 2727. CrossRef
ABO-Incompatible Living Donor Liver Transplant From a Blood Type A2 Donor to a Type B Recipient: A Note of Caution Yogesh Puri, Ashwin Rammohan, Deepti Sachan, Mukul Vij, Mohamed Rela Experimental and Clinical Transplantation.2022; 20(1): 100. CrossRef
Healthy Spouses can be Considered as Living Liver Donors Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh World Journal of Surgery.2022; 46(6): 1474. CrossRef
Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases Yuting Tang, Peipei Wu, Linli Li, Wenrong Xu, Jiajia Jiang Frontiers in Immunology.2022;[Epub] CrossRef
Overcoming high pre-transplant isoagglutinin titers using high-dose intravenous immunoglobulin, salvage plasmapheresis, and booster rituximab without splenectomy in ABO-incompatible living donor liver transplantation: a case report Hyung Hwan Moon Kosin Medical Journal.2022; 37(2): 163. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Fatal intracardiac and pulmonary arterial thromboembolic damage following ABO-incompatible living donor liver transplantation for autoimmune hepatitis Won Kyu Choi, Junghan Kim, Ho Joong Choi, Sang Hyun Hong, Min Suk Chae Medicine.2021; 100(2): e24298. CrossRef
Differences in Bile Microbiology and Antibiotic Resistances between Liver Transplant Recipients and Non-Transplant Patients Eunhye Kang, Suk-Won Suh, Seung Eun Lee, Yoo Shin Choi, Seong-Ho Choi, Bo-Ram Lee, YoungRok Choi, Jaehong Jeong Surgical Infections.2021; 22(7): 741. CrossRef
Impact of Graft Weight Change During Perfusion on Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation Jong Man Kim, Young Jae Chung, Sangjin Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Frontiers in Oncology.2021;[Epub] CrossRef
ABO-incompatible living donor liver transplantation with high preoperative antibody titer Yoshikatsu Saitoh, Atsushi Fujio, Shigehito Miyagi, Kazuaki Tokodai, Michiaki Unno, Takashi Kamei International Journal of Surgery Case Reports.2021; 85(C): 106260. CrossRef
ABO Incompatible Liver Transplantation in Children: A 20 Year Experience from Centres in the TransplantChild European Reference Network Małgorzata Markiewicz-Kijewska, Piotr Kaliciński, Juan Torres Canizales, Angelo Di Giorgio, Ulrich Baumann, Carl Jorns, Alastair Baker, Maria Francelina Lopes, Esteban Frauca Remacha, Eduardo Lopez-Granados, Paloma Jara Vega, Maria-Sole Basso, Grzegorz Ko Children.2021; 8(9): 760. CrossRef
The Human Immune Response to Cadaveric and Living Donor Liver Allografts Angus Hann, Daniel-Clement Osei-Bordom, Desley A. H. Neil, Vincenzo Ronca, Suz Warner, M. Thamara P. R. Perera Frontiers in Immunology.2020;[Epub] CrossRef
Comparison of clinical outcomes between ABO-incompatible and ABO-compatible pediatric liver transplantation: a systematic literature review and meta-analysis Zhong-Yu Kang, Wei Liu, Dai-Hong Li Pediatric Surgery International.2020; 36(11): 1353. CrossRef
Characteristics of Immunoglobulin M Type Antibodies of Different Origins from the Immunologic and Clinical Viewpoints and Their Application in Controlling Antibody-Mediated Allograft Rejection Yoshiko Matsuda, Takahisa Hiramitsu, Xiao-kang Li, Takeshi Watanabe Pathogens.2020; 10(1): 4. CrossRef
Background/Aims Twenty-four hour urinary sodium excretion (24-h UNa) of greater than 78 mmol/day is important in the management of cirrhotic ascites. Although the random urine sodium-to-potassium ratio (UNa/K) is strongly correlated with 24-h UNa, and approximately 95% of patients with a random UNa/K greater than 1 have 24-h UNa greater than 78mmol, few data have been published on the correlation between 24-h UNa and random UNa/K. We evaluated diagnostic value of morning and afternoon random UNa/K (AM UNa/K and PM UNa/K, respectively) with 24-h UNa. Methods: A total of 42 male patients were enrolled from October 2007 to March 2008. Each patient collected 5 mL of urine twice at random times during 24-h urine collection (at 10-12 a.m. and 3-5 p.m.). ROC curve analysis was performed to evaluate the feasibility of AM and PM UNa/K for differentiating 24-h UNa greater than 78mmol/day. Results: Forty patients with a 24-h urinary creatinine of greater than 15 mg/kg were analyzed. The 24-h UNa, AM UNa/K, and PM UNa/K were 107.9±91.2mmol (mean±SD), 3.44±3.64, and 3.97±4.60, respectively. When compared with 24-h UNa greater than 78 mmol, AUROC values for AM and PM UNa/K were 0.861 (95% CI, 0.715-0.950) and 0.929 (95% CI, 0.802-0.986), respectively (P=0.0001). No difference was found between the AUROC for AM and PM UNa/K (95% CI, -0.161-0.153, P=0.113). UNa/K greater than 1.25 was sensitive and specific for prediction of 24-h UNa greater than 78 mmol. Conclusions: The results suggest that anytime random UNa/K greater than 1.25 is an accurate, cost-effective, and convenient method for replacing 24-h UNa. Large multicentered cohort studies are needed to confirm our results. (Korean J Hepatol 2010; 16:66-74)
Citations
Citations to this article as recorded by
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026 Do Seon Song, Jeong-Ju Yoo, Jeong Eun Song, Seong Hee Kang, Seung Kak Shin, Seul Ki Han, Sung Won Chung, Gi-Ae Kim, Moon Haeng Hur, Han Ah Lee, Yeonjung Ha, Young Chang, Jae Hyun Yoon, Jae Seung Lee, Sang Gyune Kim, Young Kul Jung, Moon Young Kim Clinical and Molecular Hepatology.2026; 32(3): 961. CrossRef
Evaluations of Surface PM10 Concentration and Chemical Compositions in MERRA-2 Aerosol Reanalysis over Central and Eastern China Xiaodan Ma, Peng Yan, Tianliang Zhao, Xiaofang Jia, Jian Jiao, Qianli Ma, Dongqiao Wu, Zhuozhi Shu, Xiaoyun Sun, Birhanu Asmerom Habtemicheal Remote Sensing.2021; 13(7): 1317. CrossRef
Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites Jin Wook Lee, Jae Seok Hwang, Woo Jin Chung, Heon Ju Lee, Jung Gil Park, Chang Hyeong Lee, Byung Seok Kim, Jeong Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Byoung Kuk Jang, Bhagwan Dass PLOS ONE.2021; 16(6): e0253886. CrossRef
Low sodium to potassium ratio in spot urine sample is associated with progression to acute kidney injury and mortality in hospitalized patients with cirrhosis Elayne Cristina Morais Rateke, Camila Matiollo, Emerita Quintina de Andrade Moura, Michelle Andrigueti, Claudia Maccali, Janaína Sant'Ana Fonseca, Sabine Machado Fiorenza Canova, Janaína Luz Narciso-Schiavon, Leonardo Lucca Schiavon Digestive and Liver Disease.2021; 53(9): 1159. CrossRef
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications
Clinical and Molecular Hepatology.2018; 24(3): 230. CrossRef
Comparative study of spot urine Na/K ratio and 24-hour urine sodium in natriuresis evaluation of cirrhotic patients with ascites Otávio Marcos da Silva, Gabriela Bicca Thiele, Leonardo Fayad, César Lazzarotto, Esther Buzaglo Dantas-Corrêa, Leonardo de Lucca Schiavon, Janaína Luz Narciso-Schiavon GE Jornal Português de Gastrenterologia.2014; 21(1): 15. CrossRef
Avaliação da natriurese no doente cirrótico: determinação pontual Na+/K+na urina ou doseamento de sódio na urina de 24 horas? Susana Lopes GE Jornal Português de Gastrenterologia.2014; 21(1): 7. CrossRef
Can 24‐h urine sodium excretion be replaced by spot urine sodium/potassium in patients with decompensated cirrhosis? Evangelos Cholongitas, Stylianos Karatapanis, Theodora Nakouti, Charis Birtsou, Labrini Skorda, Ioannis Kouvelis, Vasilios Papastergiou, Nikolaos Papachrysos, John Goulis, Evangelos Akriviadis Liver International.2012; 32(1): 172. CrossRef
A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon
(IFN) α-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the
right upper lid and restricted right eye movement without any other neurological signs. A brain imaging study
and repetitive nerve stimulation test indicated no abnormality. The acetylcholine receptor antibody titer and
response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.
The patient’s ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN α
-2b and ribavirin. The ocular myasthenia associated with combination therapy of pegylated IFN α-2b and
ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye
complications of IFN therapy. (Korean J Hepatol 2009;15:209-215)
Citations
Citations to this article as recorded by
Autoimmune Neuromuscular Diseases Induced by Immunomodulating Drugs Songkit Supakornnumporn, Bashar Katirji Journal of Clinical Neuromuscular Disease.2018; 20(1): 28. CrossRef
Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C Su Jung Baik, Tae Hun Kim, Hye In Kim, Jeong Yeon Rhie Medicine.2016; 95(21): e3782. CrossRef
Pegylated Interferon Induced Myasthenia Crisis—A Case Report Jonathan P. Congeni, Robert B. Kirkpatrick Journal of Clinical Neuromuscular Disease.2013; 14(3): 123. CrossRef
Min Hyung Kim, M.D., Moon Seok Choi, M.D., Yong Sung Choi, M.D., Do Young Kim, M.D.,
Ji Min Lee, M.D.2, Seung Woon Paik, M.D., Joon Hyuek Lee, Kwang Cheol Koh, M.D.,
Byung Cheol Yoo, M.D., Dongil Choi, M.D.1 and Jong Chul Rhee
Background/Aims: Radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) have been applied for treating hepatocellular carcinoma (HCC), but procedure-related complications can be a serious problem. This study was conducted to evaluate the clinical features of HCC patients who developed liver abscess after RFA and TACE, as compared to those patients without malignancy. Methods: In our center, from December 1999 to March 2004, 31 cases of liver abscess developed after local treatment of HCC (13/751 after RFA and 18/8417 after TAE), which correspond to 5.1% of the total cases (602) of liver abscess. We evaluated the patients’ clinical features, the abscess characteristics, the bacteriology, treatment modality, hospital days and mortality, as compared to those characteristics of 263 abscess patients without malignancy. Results: The time required to diagnose liver abscess was longer in the TACE group (24.8±16.5 days) compared to that of the other two groups (12.2±9.0 days in the RFA group, 9.6±7.5 days in the controls, P=0.001). Gas-forming liver abscess is most frequently found in the RFA groups (76.9%). There were more hospitalized days for the TACE groups than for the RFA group and the controls (34.7±19.8 vs. 15.2±9.2 vs. 18.6±10.9 days, respectively, P<0.001). Two patients (11%) in the TACE group died of sepsis and liver failure. Conclusions: For the patients with prolonged fever after RFA and especially after TACE for HCC, a diagnosis of liver abscess should be suspected earlier to reduce the morbidity and mortality due to liver abscess per se and also the sepsis-related decompensation of the liver. (Korean J Hepatol 2006;12:55-64)
Pegylated interferon alfa-2a (PEG-IFN) and ribavirin combination therapy is the first line treatment for
chronic HCV infection. There are four reports of Bell’s palsy associated with interferon-α (IFN-α) and
ribavirin therapy. We report here a case of Bell’s palsy that occurred in a patient with chronic HCV infection
during combination PEG-IFN and ribavirin therapy. The patient was 49-year-old man with chronic hepatitis
C for 2 years. The liver biopsy showed grade 1 and stage 1. Therapy with PEG-IFN (Pegasys) 180 μg/week
and ribavirin 1200 mg/day was initiated. After 3 weeks of treatment, the patient showed a loss of muscular
tone on the left side of his face. A diagnosis of Bell’s palsy was made, and the PEG-IFN and ribavirin
therapy was stopped. Prednisolone 45 mg/d was given and then tapered for 8 weeks. His palsy improved
over 6 weeks. (Korean J Hepatol 2006;12:444-448)
Backgrounds/Aims Surgical resection is considered as a curative treatment modality for patient with hepatocellular carcinoma (HCC). Since HCC often occurs in chronic liver disease, selecting optimal candidates based on the hepatic function reserve and the risk of hepatic decompensation after resection is important. In recent studies, clinically relevant portal hypertension including hepatic venous pressure gradient (HVPG) is considered as the best predictor of postoperative hepatic decompensation. However, since measuring HVPG requires an invasive procedure it is not widely used in practice. We aimed to evaluate whether the portal hypertension diagnosed indirectly could be a useful parameter for predicting postoperative prognosis. Methods: A total of 142 patients with HCC who had endoscopic examination, computed tomography and surgical resection from January 2001 to June 2004 were included in the study. We diagnosed portal hypertension indirectly by the presence of varices or splenomegaly with thrmobocytopenia. Postoperative complications and survival rate according to the presence of portal hypertension was studied. Results: The postoperative morbidity rate was 42.2%. The incidence of ascites and prolonged hyperbilirubinemia were significantly higher in portal hypertension group (ascites 43.8 vs. 10.3%, hyperbilirubinemia 20.3 vs. 1.3%, respectively, P<0.01). The cumulative 3-year recurrence-free survival rate showed no statistical difference between the two groups. However, the cumulative 3-year survival rate was significantly higher in the non-portal hypertension group (82.8% vs. 53%, respectively, P=0.014). Conclusion: Indirectly diagnosed portal hypertension is correlated with the development of complications and poor prognosis after the surgical resection of HCC. (Korean J Hepatol 2006;12:553-561)
Kee Sup Song, M.D., Min Ju Kim, M.D., Chang Soo Jang, M.D., Hyuk Sang Jung, M.D.,
Hyun Hee Lee, M.D., Oh Sang Kwon, M.D., Yun Soo Kim, M.D., Duck Joo Choi, M.D.,
Ju Hyun Kim, M.D., Seung Yeon Ha, M.D.1
Background Most patients with acute viral hepatitis A (AVHA) spontaneously recover, but a few patients
experience complications. This study was carried out to examine clinical features of AVHA complicated with
acute renal failure (ARF). Method: Medical records of 404 patients with AVHA were reviewed. Clinical
features of AVHA patients with ARF (group A) were compared with those of AVHA patients without ARF
(group B). Result: ARF complication was present in 11 patients (3%). There were no differences between
group A and B in sex ratio and age. Microscopic hematuria (7 cases), proteinuria (7 cases), metabolic acidosis
(4 cases), oliguria (4 cases), pulmonary edema (3 cases) and hyperkalemia (2 cases) were found in group A.
The prevalence of heavy alcohol drinking (64% vs 3%, p<0.001) and diabetes mellitus (18% vs 1%, p=0.01) was
higher in group A than B. The peak value of ALT (median: 4,290 IU/L vs 1,266 IU/L, p=0.006) and total
bilirubin (median: 10.8 mg/dL vs 6.0 mg/dL, p=0.001) was higher in group A than B. Duration of admission
was longer in group A than B (median: 14 days vs 5 days, p<0.001). Four patients of group A recovered with
renal replacement therapy, while 7 patients recovered with conservative treatment. Conclusions: The AVHA
patients with ARF experienced more severe hepatitis than those without ARF, but they had a good prognosis
with the proper treatment. (Korean J Hepatol 2007;13:166-173)
First
Prev
